A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Clinical Trials, Metastatic Castration Resistant Prostate Cancer (MCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT04644770
Phase: Phase 1
Trial Summary: The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-69086420 in Part 1 (Dose Escalation) and to determine safety and and preliminary signs – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Janssen Research & Development, LLC
Acronym:

Pin It on Pinterest